In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Cardiac Regeneration in Search of Cardiac Progenitors - Challenges of cell-based therapy for heart failure

12-13 May 2011, Palace of the Acadamies, Brussels

Heart Failure (HF)


Workshop programme

Thursday 12 May 2011

Introduction
Stem cells (terminology, concepts, discordant views on origin, plasticity)
BASIC MECHANISMS OF CARDIOMYOGENESIS

Cardiac developmental biology lessons with focus on new insights in transcriptional and epigenetic pathways controlling differentiation and maturation. What can be learned from ES cells and embryology about cardiac cell fate? How to direct the fate of iPS, and pluripotent spermatogonial stem cells toward cardiac progenitors?

Cardiogenesis: an embryological perspective: lessons from cardiogenic transcriptional pathway analysis
Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors . Human induced pluripotent stem cells as a source for multipotent cardiovascular progenitors.
Functional properties of germ cell or hair follicle-derived cardiac myocytes
Functional properties of parthenogenetic stem cell derived cardiac myocytes
Bmp signaling exerts opposing effects on cardiogenic differentiation in the embryo

THE MANY FACES OF ADULT CARDIAC PROGENITOR CELLS
Do the different populations have different characteristics and does it matter? Insights into cardiac homeostasis and repair after injury.

Optimisation of human cardiac differentiation under defined conditions and selection of cell types
Guided cardiopoiesis of mesenchymal stem cells as a paradigm for cardiac maturation
Wnt/beta-catenin and SCa-1.
Isolation, expansion and functional characterization of human c-kit cardiac progenitor cells

MANIPULATING CARDIAC STEM CELLS FOR THERAPEUTIC APPLICATIONS

Do cell-related factors impact on functional repair capacity? Choice and differentiation state of cells, selected, clonogenic cell lines versus unselected heterogeneous outgrowth populations, impact of senescence on repair capacity?

MicroRNAs controlling cardiac cell fate: impact on therapeutic potency
Senescence of CSCs: functional implications?
Cardiospheres and cardiosphere-derived cells for myocardial repair: are mixed outgrowth cells superior to selected CSCs?

Friday 13 May 2011

TRANSLATIONAL APPLICATIONS OF CARDIAC STEM CELLS: BENCH TO BEDSIDE: THE OPTIMAL MILIEU FOR CELLS TO THRIVE?

Role of NO in cardiac progenitor cell maturation
Cardiac stem cells and tissue engineering
Implication of the cardiac progenitor cell niche for survival and differentiation of endogenous and transplanted progenitor cells.
Vascular progenitors: the missing link for true cardiac repair. The multifaceted progenitors with distinct phenotypes and paracrine release?
Mediators of effect: do the cells or factors released by CSCs bring the benefit – if any?

CARDIAC STEM CELLS FOR CARDIAC REPAIR: HOW TO DESIGN THE RIGHT TRIAL FOR HF PATIENTS?

Targeting HF patients that may benefit from cell transfer and how to assess in vivo effects of stem cells. Patient- and cell-related factors: How to assess the ability to mediate functional or structural repair? Autologous versus allogenic approach, cell dose and mode of administration, immunological aspects, design of trail: choice of endpoints, power, ethics…

Molecular imaging approaches to assess stem cell effects in vivo: best guide to determine cell dose, type, and mode of administration
Metabolic imaging of stem cell effects in patients: how do we evaluate it and impact on future trials?
Prespecified mesenchymal stem cells in patients with chronic ischemic dysfunction: how do we evaluate clinical effects in vivo?
Multimodal functional and structural imaging to evaluate in vivo effects of progenitor cells: tools for cell trial design in heart failure
Putting results of stem cell trials in the dysfunctional heart in perspective with recent drug trials: the heart failure trialists’ view.
The unmet need in heart failure treatment: how to target patients in need of cell therapy?